Show simple item record

dc.contributor.authorRodriguez-Ruiz, ME
dc.contributor.authorVitale, I
dc.contributor.authorHarrington, KJ
dc.contributor.authorMelero, I
dc.contributor.authorGalluzzi, L
dc.date.accessioned2021-03-24T11:25:40Z
dc.date.available2021-03-24T11:25:40Z
dc.identifier.citationNature immunology, 2020, 21 (2), pp. 120 - 134
dc.identifier.issn1529-2908
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4444
dc.identifier.eissn1529-2916
dc.identifier.doi10.1038/s41590-019-0561-4
dc.description.abstractTherapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellular and biological reconfiguration via multiple, non-redundant mechanisms. Such mechanisms include the selective elimination of particularly radiosensitive cell types and consequent loss of specific cellular functions, the local release of cytokines and danger signals by dying radiosensitive cells, and altered cytokine secretion by surviving radioresistant cells. Altogether, these processes create chemotactic and immunomodulatory cues for incoming and resident immune cells. Here we discuss how cytoprotective and cytotoxic signaling modules activated by radiation in specific cell populations reshape the immunological tumor microenvironment.
dc.formatPrint-Electronic
dc.format.extent120 - 134
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAnimals
dc.subjectHumans
dc.subjectSignal Transduction
dc.subjectCell Death
dc.subjectTumor Microenvironment
dc.titleImmunological impact of cell death signaling driven by radiation on the tumor microenvironment.
dc.typeJournal Article
dcterms.dateAccepted2019-11-14
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41590-019-0561-4
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature immunology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume21
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record